Hepatotoxicity in the treatment of acute lymphoblastic leukaemia
- 1 January 1979
- journal article
- research article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 7 (4) , 393-399
- https://doi.org/10.1002/mpo.2950070415
Abstract
Serial liver function tests and percutaneous liver biopsies were performed on 21 children receiving treatment for acute lymphoblastic leukaemia (ALL). The patients received continuing chemotherapy either with daily 6‐mercaptopurine and weekly methotrexate or with five‐day pulses of these drugs every three weeks. Liver function tests were transiently abnormal in the majority of children, but the abnormalities bore no relationship to the histology of the liver biopsy. Mild inflammatory and fatty changes were commonly seen, and early portal fibrosis was found in three out of 16 patients biopsied at between 108–130 weeks on treatment. There was no correlation between treatment regime and results of biopsy. Three patients showed possible progression of abnormalities on repeat biopsy. The risk of development of portal fibrosis appears low after 2–3 years of continuing chemotherapy, but examination of liver histology may be indicated if more prolonged therapy is contemplated.Keywords
This publication has 9 references indexed in Scilit:
- Methotrexate hepatotoxicity in children with leukemiaThe Journal of Pediatrics, 1977
- Drugs Five Years Later: MethotrexateAnnals of Internal Medicine, 1977
- Methotrexate Hepatotoxicity in Psoriasis--Comparison of Different Dose RegimensBMJ, 1972
- Liver Damage due to Methotrexate in Patients with PsoriasisBMJ, 1971
- Hepatotoxicity of Methotrexate the Treatment of PsoriasisArchives of Dermatology, 1971
- L-AsparaginaseNew England Journal of Medicine, 1969
- Hepatotoxicity of MercaptopurineJAMA, 1964
- Hepatitis in Association with Prolonged 6-Mercaptopurine TherapyBlood, 1959